Jim Cramer on Hims & Hers Health Stock

Jim Cramer shared his perspective on Hims & Hers Health, highlighting its recent performance and potential. He suggested that while buying after its pullback to $20 from recent highs around $25 might be justified, caution is advised. Cramer noted the company's strength in telehealth services, particularly in areas like sexual health and mental health, which have seen robust growth.

He emphasized that while Hims & Hers has benefited from offering compounded GLP-1 weight loss injections due to supply shortages, this revenue source is temporary. Despite this, Cramer expressed confidence in the company's overall business model and its ability to maintain strong performance beyond the GLP-1 initiative.

Cramer acknowledged the risks associated with the company's plans to transition to branded drugs in the future, which could impact margins. However, he believes in Hims & Hers' potential to sustain its growth trajectory based on its solid fundamentals and strong market position in digital health services.